Literature DB >> 16232212

Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice.

S Farkas1, M Hornung, C Sattler, M Anthuber, U Gunthert, H Herfarth, H J Schlitt, E K Geissler, B M Wittig.   

Abstract

Increased expression of CD44 variant isoforms have been shown on the inflammatory infiltrates in human and mouse colitis and blockade or deletion of CD44 isoforms inhibit experimental colitis. The objective of this study was to find out if short-term treatment of CD44 antibodies specific to CD44v7, but not to other variant isoforms, suppresses leucocyte-endothelial interaction in chronic dextran sodium sulphate (DSS)-induced colitis in mice. Chronic colitis was induced by oral administration of four cycles of 5% DSS in BALB/c mice. Expression of CD44 was investigated on isolated mononuclear cells of the gut immune system. In established colitis, mice were treated with antibodies against CD44v7 or CD44v4 three times in 7 days. Intravital microscopy was used to study leucocyte-endothelial interactions and leucocyte extravasation. As a marker of inflammatory infiltrates myeloperoxidase was quantified in gut tissue. CD44-induced apoptosis was determined by fluorescence staining of hypodiploidic cell nuclei. In chronic DSS-induced colitis both CD44 variant isoforms, v4 and v7 were significantly up-regulated on mononuclear cells. However, whereas anti-CD44v7 antibody treatment induced a marked restoration of the gut mucosa and significantly reduced endothelial sticking and extravasation of circulating leucocyte in vivo (P < 0.01), application of anti-CD44v4 or an isotype control antibody had no anti-inflammatory effect. A significant reduction of myeloperoxidase activity was detected after blockade of CD44v7, but not v4. Short-term treatment with anti-CD44v7 antibody blocks T cell extravasation and recruitment to the intestinal mucosa and cures established experimental colitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16232212      PMCID: PMC1809521          DOI: 10.1111/j.1365-2249.2005.02911.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  The CD44 variant isoforms CD44v6 and CD44v7 are expressed by distinct leukocyte subpopulations and exert non-overlapping functional activities.

Authors:  S Seiter; D S Schmidt; M Zöller
Journal:  Int Immunol       Date:  2000-01       Impact factor: 4.823

2.  TNFalpha and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44.

Authors:  M C Levesque; B F Haynes
Journal:  Cell Immunol       Date:  1999-05-01       Impact factor: 4.868

3.  Functional involvement of CD44, a family of cell adhesion molecules, in immune responses, tumour progression and haematopoiesis.

Authors:  U Günthert; C Schwärzler; B Wittig; J Laman; P Ruiz; R Stauder; A Bloem; F Smadja-Joffe; M Zöller; A Rolink
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

Review 4.  T-cell memory: the connection between function, phenotype and migration pathways.

Authors:  C R Mackay
Journal:  Immunol Today       Date:  1991-06

5.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

6.  An improved intravital microscopy system.

Authors:  A G Harris; R Hecht; F Peer; D Nolte; K Messmer
Journal:  Int J Microcirc Clin Exp       Date:  1997 Nov-Dec

7.  Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice.

Authors:  F Obermeier; G Kojouharoff; W Hans; J Schölmerich; V Gross; W Falk
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

8.  CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases.

Authors:  B Wittig; S Seiter; D S Schmidt; M Zuber; M Neurath; M Zöller
Journal:  Lab Invest       Date:  1999-06       Impact factor: 5.662

9.  Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)).

Authors:  N Hamamoto; K Maemura; I Hirata; M Murano; S Sasaki; K Katsu
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

10.  Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody.

Authors:  B Wittig; C Schwärzler; N Föhr; U Günthert; M Zöller
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

View more
  14 in total

1.  Neutrophil migration across intestinal epithelium: evidence for a role of CD44 in regulating detachment of migrating cells from the luminal surface.

Authors:  Jennifer C Brazil; Winston Y Lee; Keli N Kolegraff; Asma Nusrat; Charles A Parkos; Nancy A Louis
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

2.  Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Authors:  Bo Xiao; Zhigang Xu; Emilie Viennois; Yuchen Zhang; Zhan Zhang; Mingzhen Zhang; Moon Kwon Han; Yuejun Kang; Didier Merlin
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

3.  The synergic impact of lignin and Lactobacillus plantarum on DSS-induced colitis model via regulating CD44 and miR 199a alliance.

Authors:  Venugopal Kaliyamoorthy; Justin Packia Jacop; Krishnaraj Thirugnanasambantham; Hairul Islam Mohamed Ibrahim; Sivakumar Kandhasamy
Journal:  World J Microbiol Biotechnol       Date:  2022-10-12       Impact factor: 4.253

4.  The role of CD44 in cutaneous inflammation.

Authors:  Mona Man; Peter M Elias; Wenyan Man; Yan Wu; Lilly Y W Bourguignon; Kenneth R Feingold; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2009-03-26       Impact factor: 3.960

5.  Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature.

Authors:  Jessica S Kim; Muhammad M Bashir; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2012-03-29       Impact factor: 8.551

Review 6.  Hyaluronan, a crucial regulator of inflammation.

Authors:  Aaron C Petrey; Carol A de la Motte
Journal:  Front Immunol       Date:  2014-03-11       Impact factor: 7.561

7.  Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.

Authors:  Bo Xiao; Zhan Zhang; Emilie Viennois; Yuejun Kang; Mingzhen Zhang; Moon Kwon Han; Jiucun Chen; Didier Merlin
Journal:  Theranostics       Date:  2016-09-25       Impact factor: 11.556

8.  The Extracts of Morinda officinalis and Its Hairy Roots Attenuate Dextran Sodium Sulfate-Induced Chronic Ulcerative Colitis in Mice by Regulating Inflammation and Lymphocyte Apoptosis.

Authors:  Jian Liang; Jiwang Liang; Hairong Hao; Huan Lin; Peng Wang; Yanfang Wu; Xiaoli Jiang; Chaodi Fu; Qian Li; Ping Ding; Huazhen Liu; Qingping Xiong; Xiaoping Lai; Lian Zhou; Shamyuen Chan; Shaozhen Hou
Journal:  Front Immunol       Date:  2017-08-02       Impact factor: 7.561

Review 9.  Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.

Authors:  Fengqian Chen; Qi Liu; Yang Xiong; Li Xu
Journal:  Int J Nanomedicine       Date:  2021-06-23

10.  Osteopontin as two-sided mediator of intestinal inflammation.

Authors:  Katja Heilmann; Ute Hoffmann; Ellen Witte; Christoph Loddenkemper; Christian Sina; Stefan Schreiber; Claudia Hayford; Pamela Holzlöhner; Kerstin Wolk; Elianne Tchatchou; Verena Moos; Martin Zeitz; Robert Sabat; Ursula Günthert; Bianca Maria Wittig
Journal:  J Cell Mol Med       Date:  2008-07-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.